New pancreatic cancer drug trial stopped early
NCT ID NCT06528093
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 27 times
Summary
This early-stage study tested a new drug called BI 765883, given alone or with chemotherapy, for people with advanced pancreatic cancer that had spread or returned. The goal was to find a safe dose and see if it could shrink tumors. The study was terminated early after enrolling only 8 participants, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CTR Eugène Marquis
Rennes, 35042, France
-
CTR Leon Berard
Lyon, 69373, France
-
Cliniques Universitaires Saint-Luc
Brussels, 1200, Belgium
-
Florida Cancer Specialists-Sarasota-61670
Sarasota, Florida, 34232, United States
-
HealthONE
Denver, Colorado, 80218, United States
-
Hospital Clínic de Barcelona
Barcelona, 08036, Spain
-
Hospital Universitario Ramon Y Cajal
Madrid, 28034, Spain
-
INS Gustave Roussy
Villejuif, 94805, France
-
Klinikum der Universität München AÖR
München, 81377, Germany
-
National Cancer Center Hospital
Tokyo, Chuo-ku, 104-0045, Japan
-
National Cancer Center Hospital East
Chiba, Kashiwa, 277-8577, Japan
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UZ Leuven
Leuven, 3000, Belgium
-
Universitätsklinikum Hamburg, Eppendorf
Hamburg, 20246, Germany
-
Universitätsklinikum Heidelberg
Heidelberg, 69120, Germany
-
Yale Cancer Center
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.